Researchers report that overall survival is significantly longer among prostate cancer patients at high-risk of biochemical recurrence who are treated with combination enzalutamide and leuprolide rather than with… read more.
Nuvectis Pharma Inc, a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,… read more.
Actinium Pharmaceuticals, Inc.), a leader in the development of differentiated targeted radiotherapies announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC)… read more.
Gilead Sciences, Inc. and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for… read more.
Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting,… read more.
AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October… read more.
Australia needs to be innovative when it comes to skin cancer detection by embracing a nurse-led model that could save thousands of lives in the long run, according… read more.
Roche announced that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held 17-21… read more.
At the European Society for Medical Oncology (ESMO) Congress 2025, Boehringer Ingelheim will present new data from across its robust oncology pipeline, including non-small cell lung cancer (NSCLC)… read more.
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical… read more.
Women who don’t turn up for their first breast screening appointment face a 40% higher long term risk of dying from breast cancer, mainly due to delayed detection,… read more.
CEO: Haruo Naito, announced the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2025, which is taking… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
